HK1005225A1 - Interferon conjugates - Google Patents

Interferon conjugates

Info

Publication number
HK1005225A1
HK1005225A1 HK98104388A HK98104388A HK1005225A1 HK 1005225 A1 HK1005225 A1 HK 1005225A1 HK 98104388 A HK98104388 A HK 98104388A HK 98104388 A HK98104388 A HK 98104388A HK 1005225 A1 HK1005225 A1 HK 1005225A1
Authority
HK
Hong Kong
Prior art keywords
interferon conjugates
conjugates
interferon
Prior art date
Application number
HK98104388A
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Alicia Vallejo Palleroni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1005225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1005225A1 publication Critical patent/HK1005225A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK98104388A 1996-05-31 1998-05-21 Interferon conjugates HK1005225A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
HK1005225A1 true HK1005225A1 (en) 1998-12-31

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104388A HK1005225A1 (en) 1996-05-31 1998-05-21 Interferon conjugates

Country Status (48)

Country Link
US (1) US7201897B2 (hu)
EP (1) EP0809996B1 (hu)
JP (1) JP2980569B2 (hu)
KR (1) KR100254097B1 (hu)
CN (1) CN1088721C (hu)
AR (1) AR008378A1 (hu)
AT (1) ATE235920T1 (hu)
AU (1) AU725195B2 (hu)
BG (1) BG62273B1 (hu)
BR (1) BR9703421A (hu)
CA (1) CA2203480C (hu)
CO (1) CO4950528A1 (hu)
CY (2) CY2433B1 (hu)
CZ (1) CZ292775B6 (hu)
DE (3) DE10399018I1 (hu)
DK (1) DK0809996T3 (hu)
EG (1) EG24292A (hu)
ES (1) ES2110386T3 (hu)
GR (1) GR970300063T1 (hu)
HK (1) HK1005225A1 (hu)
HR (1) HRP970298B1 (hu)
HU (1) HU227992B1 (hu)
IL (1) IL120902A (hu)
IS (1) IS1988B (hu)
LU (1) LU91029I2 (hu)
MA (1) MA24193A1 (hu)
MY (1) MY117909A (hu)
NL (1) NL300127I2 (hu)
NO (1) NO322964B1 (hu)
NZ (1) NZ314903A (hu)
OA (1) OA10488A (hu)
PA (1) PA8431001A1 (hu)
PL (1) PL186949B1 (hu)
PT (1) PT809996E (hu)
RS (1) RS49533B (hu)
RU (1) RU2180595C2 (hu)
SA (1) SA97180030B1 (hu)
SG (1) SG55314A1 (hu)
SI (1) SI0809996T1 (hu)
SK (1) SK284458B6 (hu)
SV (1) SV1997000049A (hu)
TJ (1) TJ328B (hu)
TN (1) TNSN97091A1 (hu)
TR (1) TR199700358A2 (hu)
TW (1) TW517067B (hu)
UA (1) UA56989C2 (hu)
UY (1) UY24572A1 (hu)
ZA (1) ZA974583B (hu)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1997016204A1 (en) 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
PT1075281E (pt) * 1998-04-28 2004-11-30 Applied Research Systems Conjugados poliol-ifn-beta
ES2172288T3 (es) 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
SI1087778T1 (sl) * 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CO5170404A1 (es) 1999-04-08 2002-06-27 Schering Corp Terapia para melanomas
TWI271196B (en) * 1999-04-08 2007-01-21 Schering Corp CML therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
NZ520261A (en) 2000-01-10 2003-10-31 Maxygen Holdings Ltd Granulocyte colony-stimulating factor PEG conjugates that exhibit an increased bioavailability and half-life in vivo and reduced side effects and immunogenicity
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
CA2397793A1 (en) * 2000-01-24 2001-07-26 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6927040B2 (en) 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
US7291713B2 (en) 2001-01-30 2007-11-06 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
CA2469846A1 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US8048408B2 (en) * 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
KR100888371B1 (ko) * 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
CN101301475B (zh) 2002-06-21 2012-12-19 诺和诺德医疗保健公司 Peg化因子vii糖型
PL375265A1 (en) 2002-07-24 2005-11-28 F.Hoffmann-La Roche Ag Polyalkylene glycol acid additives
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
JP2006516534A (ja) 2002-09-11 2006-07-06 フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｈａｓ化ポリペプチド、特にｈａｓ化エリスロポエチン
ES2214166T1 (es) * 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005035565A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
JP4971160B2 (ja) 2004-08-12 2012-07-11 シェーリング コーポレイション 安定するｐｅｇ化インターフェロン処方物
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
CN101501068A (zh) 2005-05-18 2009-08-05 马克西根公司 改进的α-干扰素多肽
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
JP2008543943A (ja) * 2005-06-20 2008-12-04 ペプゲン コーポレイション ヒトインターフェロンアルファ類似体とインターフェロンタウの低毒性長期循環性キメラ
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
WO2007132882A1 (ja) 2006-05-16 2007-11-22 Tokyo Metropolitan Organization For Medical Research Hcv感染症を治療または予防するための医薬組成物
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CN1966547B (zh) * 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
WO2008055666A1 (en) * 2006-11-07 2008-05-15 Dsm Ip Assets B.V. Carbamate, thiocarbamate or carbamide comprising a biomolecular moiety
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CN101636414B (zh) 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2245044A2 (en) * 2008-01-18 2010-11-03 F. Hoffmann-La Roche AG Purification of non-glycosylated proteins
DK2237799T3 (da) * 2008-02-01 2019-06-11 Ascendis Pharma As Prodrug omfattende en selv-spaltbar linker
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
DK2272875T3 (da) 2008-04-03 2014-03-31 Biosteed Gene Expression Tech Co Ltd Dobbeltstrenget polyethylenglycolmodificeret væksthormon, fremstillingsmetode samt anvendelse deraf
SI2279007T1 (sl) * 2008-04-29 2016-09-30 Ascendis Pharma Growth Disorders Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8143412B2 (en) 2008-07-08 2012-03-27 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
CN103209709A (zh) 2010-08-05 2013-07-17 弗·哈夫曼-拉罗切有限公司 抗mhc抗体抗病毒性细胞因子融合蛋白
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
SG10201606395XA (en) 2011-08-03 2016-09-29 Cytheris Hcv immunotherapy
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EA022617B1 (ru) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA023323B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
MX2017005244A (es) * 2014-11-06 2017-08-18 Pharmaessentia Corp Regimen de dosificacion para interferon pegilado.
AU2016349685A1 (en) 2015-11-03 2018-03-15 F. Hoffmann-La Roche Ag Combination therapy of an HBV capsid assembly inhibitor and an interferon
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
DK0400472T3 (da) * 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
NZ276943A (en) * 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
JP2980569B2 (ja) 1999-11-22
TJ328B (en) 2001-12-24
EP0809996B1 (en) 2003-04-02
EG24292A (en) 2009-01-08
CA2203480C (en) 2009-06-30
MX9704012A (es) 1997-11-29
BG101540A (en) 1998-02-27
UY24572A1 (es) 2000-12-29
IL120902A0 (en) 1997-09-30
MY117909A (en) 2004-08-30
UA56989C2 (uk) 2003-06-16
AU725195B2 (en) 2000-10-05
IL120902A (en) 2004-06-20
US20040030101A1 (en) 2004-02-12
US7201897B2 (en) 2007-04-10
HRP970298A2 (en) 1998-04-30
HUP9700959A2 (hu) 1998-03-02
ES2110386T1 (es) 1998-02-16
AU2372397A (en) 1997-12-04
PL186949B1 (pl) 2004-04-30
KR100254097B1 (ko) 2000-05-01
PA8431001A1 (es) 2000-05-24
JPH1067800A (ja) 1998-03-10
TJ97000465A (en) 1998-12-25
OA10488A (fr) 2002-04-11
TW517067B (en) 2003-01-11
RS49533B (sr) 2006-12-15
SA97180030B1 (ar) 2005-11-12
PL320251A1 (en) 1997-12-08
EP0809996A3 (en) 1999-04-14
SV1997000049A (es) 1998-07-09
DE69720320T2 (de) 2004-06-03
NZ314903A (en) 1998-10-28
DK0809996T3 (da) 2003-07-21
HUP9700959A3 (en) 1998-03-30
IS1988B (is) 2005-02-15
CY2005006I1 (el) 2009-11-04
LU91029I2 (fr) 2004-01-23
SK67397A3 (en) 1997-12-10
IS4491A (is) 1997-12-01
SG55314A1 (en) 1998-12-21
HRP970298B1 (en) 2003-08-31
NL300127I1 (hu) 2003-07-01
ZA974583B (en) 1998-11-17
PT809996E (pt) 2003-06-30
NL300127I2 (nl) 2003-09-01
ES2110386T3 (es) 2003-10-01
CZ167997A3 (en) 1997-12-17
RU2180595C2 (ru) 2002-03-20
TR199700358A3 (tr) 1997-12-21
HU9700959D0 (en) 1997-07-28
CN1167777A (zh) 1997-12-17
NO972480D0 (no) 1997-05-30
GR970300063T1 (en) 1998-01-30
DE69720320D1 (de) 2003-05-08
BR9703421A (pt) 1998-09-15
BG62273B1 (bg) 1999-07-30
KR970074791A (ko) 1997-12-10
SI0809996T1 (en) 2003-08-31
SK284458B6 (sk) 2005-04-01
CY2433B1 (en) 2004-11-12
CA2203480A1 (en) 1997-11-30
YU17597A (sh) 1999-07-28
MA24193A1 (fr) 1997-12-31
ATE235920T1 (de) 2003-04-15
NO322964B1 (no) 2006-12-18
CO4950528A1 (es) 2000-09-01
EP0809996A2 (en) 1997-12-03
AR008378A1 (es) 2000-01-19
CY2005006I2 (el) 2009-11-04
NO972480L (no) 1997-12-01
CZ292775B6 (cs) 2003-12-17
CN1088721C (zh) 2002-08-07
DE10399018I1 (de) 2003-10-23
TNSN97091A1 (fr) 2005-03-15
TR199700358A2 (xx) 1997-12-21
HU227992B1 (en) 2012-08-28
DE809996T1 (de) 1998-04-09

Similar Documents

Publication Publication Date Title
EG24292A (en) Interferon conjugates
ZA9811590B (en) Interferon polymer conjugates
GB9713980D0 (en) New conjugates
DE59700372D1 (en) Blockcopolymere
IL116456A0 (en) Oligonucleotide-dendrimer conjugates
DE59703905D1 (en) Linearmotorgetriebene transportanlage
DE59704086D1 (en) Twin-dualmode-filter
GB9623184D0 (en) Special X
DE59702027D1 (en) Bragg-modulator
DE59703023D1 (en) Cyclopeptidderivate
AU131132S (en) Handleset
AU131198S (en) Handleset
GB2310359B (en) Improvements ih half-chaps
DE59610178D1 (en) Rotationspumpe
AU131131S (en) Handleset
AU131199S (en) Handleset
ZA9510827B (en) Oligonucleotide-dendrimer conjugates
CA79582S (en) Jerkin
AU1593P (en) Songlines Telopea speciosissima
GB9621604D0 (en) Le Sneck
ZA9810108B (en) Moving arrangement
AU1996120V (en) CASBAH Biserrula pelecinus
AU127913S (en) Gamesboard
AU128195S (en) Campervan
AU129869S (en) Multi-stool

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170521